Celerion has expanded its ADME (Absorption, Distribution, Metabolism and Excretion) suite in Lincoln, NE. The company invested in new equipment and lab space to perform on-site scintillation counting allowing for radioactivity recovery results to be delivered in real-time. This service aims to ensure high total recovery of radioactive dose while providing for efficient clinical study conduct.
 
“The enhancement in our facility was driven by client needs, including a growing interest in conducting these critical studies earlier in a drug’s development.  This is a response to regulatory guidances concerning knowledge of human metabolism and metabolites during safety assessment,” said Raymond Farmen, vice president, Global Bioanalytical Services. “The on-site bioanalytical and Phase I clinical facilities in Lincoln offer seamless integration of services and data. For bioanalytical analyses, the ADME suite interfaces with Celerion’s global electronic laboratory notebook system thereby increasing data compliance.”